Forskningsparken, Oslo Science Park · 19–21 May 2027
About the workshop
From method development to clinical trials
We wanted a forum to focus specifically on imaging and dosimetry of alpha therapies, and created this workshop to learn, discuss and develop methods that improve how we approach clinical trials of alpha therapies. Through the workshop we address topics from various stages of development and implementation, while exploring potential solutions at both an overarching and a radionuclide level.
Key dates
Invited speakers
Invited talks across the three days
-
Øyvind Bruland
The story behind the development of Xofigo
Day 1 · Introduction and history of alpha therapy
-
Pablo Mínguez Gabiña
Clinical imaging of 223Ra
Day 1 · Clinical imaging and non-imaging measurements I
-
François Paquet
Benefits and pitfalls of using ICRP publications on occupational intakes of radionuclides for radionuclide therapies
Day 2 · Biokinetic and pharmacokinetic models
-
Peter Bernhardt
Strategies for nuclear medicine image reconstructions for alpha-particle emitters
Day 2 · Reconstruction
-
Asta Juzeniene
Development of new alpha therapies
Day 2 · Small-scale dosimetry, radiobiology and preclinical development
-
Stephen Graves
Experience from early phase targeted alpha therapy studies with 212Pb
Day 3 · Imaging and dosimetry in clinical studies I
-
Caroline Stokke
Imaging and dosimetry for alpha emitters: how to plan clinical trials
Day 3 · Imaging and dosimetry in clinical studies II
Talk titles are provisional.
Alpha therapy began here
Oslo is where the first approved alpha therapy was developed
Radium-223 dichloride, later approved as Xofigo, was developed in Oslo in the 1990s by Roy Larsen and Øyvind Bruland at the Norwegian Radium Hospital, today part of Oslo University Hospital and the same trust that hosts this workshop.
In 2013 it became the first alpha-emitting therapy approved for clinical use, after the ALSYMPCA trial showed it extended survival in men with castration-resistant prostate cancer and bone metastases. We are looking forward to Øyvind Bruland’s talk on the early development of Xofigo, and hope the workshop can contribute new ideas for the alpha therapies of the future.
Hosted by
The Theragnostic Imaging research group
The workshop is arranged by the Theragnostic Imaging research group at Oslo University Hospital. Founded in 2017 by Caroline Stokke, the group works on molecular imaging, biodistribution, dosimetry and treatment planning for radionuclide therapies.
Its current work includes imaging and modelling approaches for developing alpha therapies, dosimetry in clinical trials, and the RNTreg registry for radionuclide therapy.
Venue
Forskningsparken, Oslo Science Park
A central innovation and research environment in Oslo, well connected to the University of Oslo, hospitals, public transport and the city centre.